Durect corporation to announce third quarter 2024 financial results and provide a business update

Cupertino, calif. , nov. 6, 2024 /prnewswire/ -- durect corporation (nasdaq: drrx), a late-stage biopharmaceutical company pioneering the development of epigenetic therapies to transform the treatment of serious and life-threatening conditions, including acute organ injury, today announced that the company will report its third quarter financial results on wednesday, november 13, 2024.
DRRX Ratings Summary
DRRX Quant Ranking